Lausanne University Hospital
Lausanne, Canton of Vaud, 1011, Switzerland
NCT Number: NCT04999566
The aim of this study is to report and describe cardiac manifestations associated with IMD in a cohort of patients followed in a reference center for rare diseases (Lausanne University Hospital, CHUV) from 2017-2020.
Looking for future studies?
Notify Me16 year and older
All sexes
Observational
Lausanne, Canton of Vaud, 1011, Switzerland
Inherited metabolic diseases (IMD) are genetic disorders resulting from an enzyme defect and/or transport proteins in metabolic pathways affecting proteins, fat, carbohydrate metabolism or impaired organelle function. As IMDs can affect the primary sources of energy (glycogen, fatty acids), they can lead to cardiac dysfunction. Although most of IMDs are multisystemic diseases, in some cases, the cardiac dysfunction they cause is the main clinical feature and source of major complications which will determine the prognosis, like heart failure, ventricular arrythmias or even sudden death. Information regarding cardiac manifestations in adult IMDs is currently scarce and little is known about their clinical and radiological characteristics.
A database was created in 2017 including all patients with IMD followed at the Adult Metabolic Clinic in the CHUV. This database was part of a protocol submitted and approved by the Ethics committee (# 2017-02328). The results of this first analysis were published in the Journal of Orphan Rare Diseases. Investigators will use this database to identify all the patients who had cardiac examination. Only patients from the Lausanne University Hospital followed jointly with the Division of Cardiology will be included in the analysis. Electronic and paper patient charts from the Division of Genetic Medicine and Division of Cardiology (Lausanne University Hospital) will be reviewed for type of IMD and cardiac investigations (cardiac ultrasound, multiple resonance Imaging, electrocardiogram). All variables will be entered in an excel database.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 1
Clinical outcome
Time frame: Day 1
Clinical outcome
Time frame: through study completion, an average of 1 year
Clinical outcome
Time frame: through study completion, an average of 1 year
Clinical outcome
Time frame: through study completion, an average of 1 year
Clinical outcome
Time frame: through study completion, an average of 1 year
Clinical outcome. Weight and height will be combined to report BMI
Time frame: 3 years
Type of complications (restrictive cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrythmia, heart failure, valvlulopathy, cardiomegaly, thrombosis)
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of left ventricular mass
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of left ventricular volume
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of right ventricular volume
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of left ventricular diameter
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of left ventricular ejection fraction
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of right ventricular ejection fraction
Time frame: 3 years
Cardiac ultrasound and multiple resonance imaging description of aortic root diameter
Time frame: 3 years
ECG-QT interval
Time frame: 3 years
Treatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, vitamin cofactors
Time frame: Day 1
Demography outcome
University of Lausanne
Other
Cardiac Manifestations in Adult Patients With Inherited Metabolic Disease: a Case Series
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05123768
Aromatic amino acid decarboxylase deficiency, Ataxia
Ljubljana, Slovenia
View Trial DetailsNCT02826694
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ear Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT00362180
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Amsterdam, Netherlands
View Trial DetailsNCT00477594
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Chicago, Illinois, United States
View Trial Details